Vogelsang G B, Hess A D, Gordon G, Santos G W
Transplantation. 1986 May;41(5):644-7. doi: 10.1097/00007890-198605000-00018.
We have investigated the immunosuppressive effects of thalidomide (Thal) in a bone marrow transplant (BMT) model for graft-versus-host disease (GVHD). Lewis rats received RT1-incompatible marrow transplants from ACI rats after total-body irradiation. Twenty-two of twenty-three rats with established severe acute GVHD were successfully treated with Thal. Thal was given for therapy by gavage at 50 mg/kg/day or 100 mg/kg/day for 40 days after GVHD was clinically and histologically present. Fourteen of twenty-two received prophylaxis successfully with Thal at a dose of 50 mg/kg/day or 100 mg/kg/day. Acute GVHD did not develop after the drug was stopped. Three animals treated for severe GVHD later developed chronic GVHD. Chimerism was shown by permanent acceptance of ACI skin grafts and rejection of third-party skin grafts. Lymphocytes from Thal-treated animals likewise did not respond to Lewis or ACI cells in mixed lymphocyte culture but responded to third-party BN lymphocytes. Thal appears to be a potent new agent for therapy and prophylaxis of GVHD.
我们在移植物抗宿主病（GVHD）的骨髓移植（BMT）模型中研究了沙利度胺（Thal）的免疫抑制作用。经全身照射后，Lewis大鼠接受了来自ACI大鼠的RT1不相容骨髓移植。23只已确诊为严重急性GVHD的大鼠中有22只成功接受了Thal治疗。在临床和组织学上出现GVHD后，以50mg/kg/天或100mg/kg/天的剂量通过灌胃给予Thal进行治疗，持续40天。22只大鼠中有14只以50mg/kg/天或100mg/kg/天的剂量成功接受了Thal预防。停药后未发生急性GVHD。3只接受严重GVHD治疗的动物后来发生了慢性GVHD。通过永久接受ACI皮肤移植和排斥第三方皮肤移植显示出嵌合体现象。来自接受Thal治疗动物的淋巴细胞在混合淋巴细胞培养中同样对Lewis或ACI细胞无反应，但对第三方BN淋巴细胞有反应。Thal似乎是一种治疗和预防GVHD的有效新药。
